background
object
studi
assess
efficaci
trival
vaccin
mixtur
compar
respect
monoval
vaccin
mycoplasma
hyopneumonia
porcin
circoviru
type
porcin
reproduct
respiratori
syndrom
viru
prrsv
result
pig
tripl
challeng
hyopneumonia
prrsv
follow
vaccin
trival
vaccin
mixtur
exhibit
significantli
better
growth
perform
compar
unvaccin
challeng
pig
statist
differ
found
compar
pig
popul
vaccin
trival
vaccin
follow
tripl
challeng
pig
vaccin
monoval
hyopneumonia
vaccin
follow
mycoplasm
singl
challeng
follow
area
hyopneumonia
nasal
shed
number
hyopneumoniaespecif
secret
cell
mycoplasm
lung
lesion
score
pig
vaccin
trival
vaccin
mixtur
follow
tripl
challeng
result
similar
reduct
viremia
increas
number
reduct
interstiti
lung
lesion
score
compar
pig
vaccin
vaccin
challeng
lastli
signific
differ
reduct
prrsv
viremia
increas
prrsvspecif
reduct
interstiti
lung
lesion
score
pig
vaccin
trival
vaccin
mixtur
follow
tripl
challeng
pig
vaccin
monoval
prrsv
vaccin
follow
prrsv
challeng
conclus
trival
vaccin
mixtur
efficaci
tripl
challeng
hyopneumonia
prrsv
trival
vaccin
mixtur
howev
result
equal
protect
compar
respect
monoval
vaccin
largest
vaccin
occur
within
prrsv
porcin
respiratori
diseas
complex
prdc
diseas
predomin
affect
grow
finish
pig
age
week
commonli
refer
wall
modern
commerci
pig
product
multipl
factor
contribut
prdc
includ
multipl
viral
bacteri
infect
environment
condit
manag
practic
clinic
sign
character
slow
uneven
growth
decreas
feed
effici
anorexia
fever
cough
dyspnea
current
prdc
one
biggest
health
concern
asian
swine
industri
etiolog
agent
associ
prdc
may
vari
differ
geograph
region
asia
mycoplasma
hyopneumonia
porcin
circoviru
type
porcin
reproduct
respiratori
syndrom
viru
prrsv
primari
pathogen
caus
major
prdc
case
result
devast
econom
loss
asian
swine
produc
control
prdc
use
prevent
vaccin
rather
antibiot
combin
vaccin
prefer
order
reduc
pig
stress
decreas
labor
cost
trival
vaccin
mixtur
boehring
ingelheim
vetmedica
st
joseph
missouri
usa
hyopneumonia
prrsv
licens
mani
asian
countri
control
prdc
howev
concern
swine
produc
trival
vaccin
mixtur
may
less
effect
compar
respect
monoval
vaccin
current
avail
possibl
interfer
among
mix
antigen
studi
decid
evalu
efficaci
trival
vaccin
mixtur
boehring
ingelheim
vetmedica
tripl
challeng
hyopneumonia
prrsv
compar
efficaci
respect
monoval
vaccin
clinic
immunolog
microbiolog
patholog
paramet
chosen
evalu
mean
score
respiratori
diseas
significantli
higher
p
pig
group
compar
vacmhp
chmhp
unvacchmhp
unvacunch
group
dpc
fig
unvacunch
group
dpc
fig
mean
respiratori
score
significantli
higher
p
pig
unvacchprrsv
group
compar
vacprrschprrsv
unvac
unch
group
dpc
fig
statist
differ
observ
averag
bodi
weight
mean
standard
deviat
among
group
day
age
start
studi
n
kg
vacmhp
chmhp
n
kg
n
kg
vacprrschprrsv
n
kg
n
kg
unvac
chmhp
n
kg
n
kg
unvacchprrsv
n
kg
unvacunch
n
kg
overal
adwg
day
old
pig
vacmhpchmhp
vacprrschprrsv
unvacchmhp
unvacchprrsv
unvacunch
group
significantli
higher
p
compar
unvac
group
tabl
prior
challeng
genom
copi
hyopneumonia
prrsv
detect
pig
group
pig
vacmhpchmhp
group
significantli
less
p
hyopneumonia
genom
copi
nasal
swab
compar
unvac
chmhp
group
dpc
pig
vacmhp
chmhp
group
significantli
lower
p
number
hyopneumonia
genom
copi
nasal
swab
compar
group
dpc
fig
pig
group
significantli
lower
p
number
genom
copi
blood
compar
group
dpc
pig
group
significantli
lower
p
number
genom
copi
blood
compar
group
dpc
fig
vacprrschprrsv
group
significantli
lower
p
number
genom
copi
prrsv
blood
compar
unvacchprrsv
group
dpc
vacprrschprrsv
group
significantli
lower
p
number
genom
copi
prrsv
blood
compar
group
dpc
unvacchprrsv
group
significantli
lower
p
number
genom
copi
prrsv
blood
compar
group
dpc
genom
copi
prrsv
detect
pig
unvacunch
group
fig
genom
copi
hyopneumonia
prrsv
detect
pig
unvacunch
group
antibodi
respons
hyopneumonia
assess
elisa
pig
vacmhpchmhp
group
significantli
higher
p
hyopneumonia
elisa
sp
ratio
compar
unvacchmhp
group
dpc
pig
group
also
significantli
higher
p
hyopneumonia
elisa
sp
ratio
compar
group
dpc
fig
pig
group
significantli
higher
p
elisa
titer
compar
group
dpc
fig
vacprrschprrsv
group
significantli
higher
p
prrsv
elisa
sp
ratio
compar
unvac
chprrsv
group
dpc
unvac
chprrsv
group
significantli
higher
p
fig
mean
respiratori
score
trival
vaccin
mixtur
respect
monoval
hyopneumonia
vaccin
b
mean
respiratori
score
trival
vaccin
mixtur
respect
monoval
vaccin
c
mean
respiratori
score
trival
vaccin
mixtur
respect
monoval
prr
vaccin
variat
express
standard
deviat
differ
letter
within
sampl
point
mean
statist
signific
differ
p
prrsv
elisa
sp
ratio
compar
group
dpc
fig
antibodi
hyopneumonia
prrsv
detect
pig
unvacunch
group
fig
pig
group
neg
influenza
viru
antibodi
cell
respons
number
hyopneumoniaespecif
quantifi
pbmc
individu
pig
pig
vacmhp
chmhp
group
significantli
higher
p
number
hyopneumoniaespecif
pbmc
compar
unvacchmhp
group
dpc
fig
cell
respons
evalu
compar
number
pig
group
significantli
higher
p
number
pbmc
compar
group
dpc
pig
group
significantli
higher
p
number
pbmc
compar
dpc
fig
vacprrschprrsv
group
significantli
higher
p
number
prrsvspecif
pbmc
compar
unvac
unvacchprrsv
group
dpc
vacprrschprrsv
unvac
chprrsv
group
significantli
higher
p
number
prrsvspecif
pbmc
compar
group
dpc
fig
mean
number
hyopneumonia
prrsvspecif
unvacunch
group
remain
basal
level
pbmc
throughout
studi
pig
vacmhpchmhp
group
significantli
lower
p
macroscop
lung
lesion
score
microscop
mycoplasm
interstiti
lung
lesion
score
compar
group
dpc
pig
vacmhpchmhp
group
significantli
lower
p
macroscop
lung
lesion
score
microscop
mycoplasm
lung
lesion
score
compar
unvacchmhp
group
dpc
tabl
pig
group
significantli
lower
p
macroscop
lung
lesion
score
microscop
mycoplasm
interstiti
lung
lesion
score
compar
unvac
group
dpc
pig
group
significantli
lower
p
microscop
interstiti
lung
lesion
score
compar
group
dpc
tabl
vacprrschprrsv
unvac
chprrsv
group
significantli
lower
p
macroscop
lung
lesion
score
microscop
mycoplasm
interstiti
lung
lesion
score
compar
group
dpc
vacprrschprrsv
group
significantli
lower
p
macroscop
lung
lesion
score
microscop
interstiti
lung
lesion
score
compar
unvacchprrsv
group
dpc
differ
letter
mean
statist
signific
differ
within
group
p
macroscop
microscop
lung
lesion
observ
pig
unvacunch
group
tabl
assess
efficaci
trival
vaccin
mixtur
hyopneumonia
prrsv
compar
respect
monoval
vaccin
unvaccin
posit
control
group
trival
vaccin
mixtur
abl
reduc
clinic
sign
lung
lesion
prrsv
viremia
improv
weight
gain
compar
unvaccin
posit
control
group
trival
vaccin
mixtur
howev
result
equal
protect
compar
respect
monoval
vaccin
largest
vaccin
occur
within
prrsv
although
prr
vaccin
studi
wide
use
efficaci
commerci
avail
prrsv
vaccin
continu
global
challeng
prrsv
variant
strain
continu
emerg
highli
pathogen
outbreak
particularli
asia
pig
vaccin
trival
vaccin
follow
tripl
challeng
significantli
improv
growth
perform
compar
unvaccin
control
pig
contrast
growth
perform
better
significantli
differ
hyopneumonia
vaccin
control
pig
follow
hyopneumonia
challeng
result
consist
previou
find
signific
differ
growth
perform
observ
hyopneumoniaevaccin
unvaccin
pig
follow
hyopneumonia
challeng
signific
differ
growth
perform
also
observ
prrsvaccin
control
pig
possibl
reason
lack
statist
signific
could
growth
perform
pig
vaccin
monoval
vaccin
evalu
week
singl
challeng
addit
growth
retard
singl
challeng
like
sever
therefor
improv
growth
perform
monoval
vaccin
drastic
tripl
challeng
typic
sever
singl
challeng
addit
field
studi
infect
hyopneumonia
prrsv
increas
chanc
opportunist
secondari
bacteri
infect
could
result
growth
retard
howev
observ
decreas
growth
perform
due
secondari
bacteri
infect
experiment
studi
taken
togeth
result
suggest
growth
perform
import
paramet
prdc
control
without
control
hyopneumonia
hyopneumonia
infect
exacerb
lung
lesion
caus
prrsv
infect
pig
addit
previou
work
shown
hyopneumonia
vaccin
reduc
interstiti
pneumonia
caus
prrsv
therefor
control
hyopneumonia
first
step
control
prdc
caus
three
challeng
pathogen
use
studi
trival
vaccin
mixtur
monoval
hyopneumonia
vaccin
abl
elicit
similar
number
hyopneumoniaespecif
vaccin
pig
import
sinc
cellmedi
immun
measur
shown
play
import
role
control
hyopneumonia
infect
induct
cellmedi
immun
also
associ
signific
reduct
amount
hyopneumonia
nasal
shed
vaccin
trival
product
result
compar
reduct
hyopneumonia
nasal
shed
lung
lesion
respect
hyopneumonia
monoval
compar
efficaci
trival
vaccin
mixtur
monoval
vaccin
look
cellmedi
immun
elicit
vaccin
import
immun
mechan
contribut
clearanc
blood
addit
posit
correl
report
viremia
sever
observ
lesion
therefor
induct
reduct
viremia
critic
paramet
evalu
vaccin
studi
signific
differ
number
reduct
viremia
trival
vaccin
mixtur
monoval
vaccin
lastli
compar
efficaci
trival
vaccin
mixtur
prrsv
monoval
prr
vaccin
unvaccin
posit
control
reduct
viremia
lung
lesion
induct
cellmedi
immun
specif
prrsvspecif
use
assess
antigenspecif
tcell
respons
swine
import
criteria
prrsv
vaccin
evalu
despit
fact
protect
role
controversi
correl
activ
cell
respons
clearanc
prrsv
blood
previous
report
data
suggest
cell
respons
elicit
prrsv
mlv
vaccin
play
role
reduct
prrsv
viremia
vaccinatedchalleng
pig
studi
vaccin
either
trival
vaccin
mixtur
monoval
prr
vaccin
result
induct
cell
respons
reduct
viral
load
blood
simultan
addit
statist
differ
number
prrsvspecif
level
prrsv
viremia
lung
lesion
score
trival
vaccin
monoval
vaccin
pig
studi
present
evid
trival
vaccin
mixtur
efficaci
challeng
three
pathogen
hyopneumonia
prrsv
similar
efficaci
individu
monoval
vaccin
respect
singl
challeng
addit
interfer
studi
would
need
conduct
establish
ratio
determin
compat
trival
vaccin
mixtur
compar
respect
monoval
vaccin
especi
regard
effect
viabil
prrsv
mlv
vaccin
addit
difficult
draw
full
conclus
direct
comparison
respect
monoval
vaccin
differ
challeng
inocula
trival
vaccin
mixtur
group
monoval
vaccin
group
addit
test
group
pig
vaccin
monoval
vaccin
follow
tripl
challeng
vaccin
trival
vaccin
mixtur
follow
singl
challeng
either
hyopneumonia
prrsv
includ
evalu
result
studi
demonstr
trival
vaccin
significantli
efficaci
tripl
challeng
three
challeng
strain
use
studi
includ
prrsv
strain
lineag
genbank
hyopneumonia
strain
strain
genbank
sever
key
reason
play
import
role
defin
strain
select
hyopneumonia
strain
produc
lesion
typic
hyopneumonia
found
within
peribronchi
peribronchiolar
lymphoid
tissu
hyperplasia
lung
infect
pig
prrsv
strain
caus
interstiti
pneumonia
lung
infect
pig
strain
caus
mild
lymphoid
deplet
lymph
node
infect
pig
tripl
challeng
use
hyopneumonia
strain
prrsv
strain
strain
also
produc
similar
clinic
symptom
piglet
use
studi
select
base
breed
herd
neg
serolog
screen
prrsv
hyopneumonia
prior
purchas
long
term
clinic
slaughter
histori
also
taken
account
piglet
select
studi
nasal
swab
hyopneumonia
also
collect
test
realtim
pcr
serum
nasal
swab
produc
neg
result
random
number
gener
function
excel
microsoft
corpor
redmond
washington
usa
use
randomli
divid
piglet
group
tabl
minimum
sampl
size
per
group
calcul
suggest
cohen
use
pwr
packag
r
r
core
team
languag
environ
statist
comput
r
foundat
statist
comput
vienna
austria
http
wwwrprojectorg
signific
level
effect
size
power
use
calcul
minimum
number
piglet
need
per
group
valu
determin
therefor
least
piglet
design
per
group
blind
personnel
defin
personnel
could
identifi
vaccin
statu
pig
perform
action
includ
administr
vaccin
administr
pb
control
record
observ
pull
defin
measur
studi
conduct
seoul
nation
univers
depart
veterinari
patholog
contain
hepafilt
isol
one
room
contain
pig
group
room
contain
pen
individu
pig
hous
per
pen
vaccin
group
randomli
assign
includ
pig
femal
male
split
two
room
pig
per
room
unvaccin
group
assign
pig
male
femal
hous
singl
room
random
number
gener
excel
microsoft
corpor
use
assign
pig
group
room
sever
key
hous
element
taken
consider
slat
solid
surfac
pen
floor
room
lit
hday
light
intens
set
lx
order
simul
daytim
temperatur
room
also
kept
constant
water
avail
piglet
drink
freeli
throughout
day
via
nippl
drinker
place
pen
pen
addit
equip
selffeed
provid
access
standardbalanc
ageappropri
pellet
feed
diet
playtim
stimul
offer
place
rubber
ball
pen
day
post
challeng
dpc
day
old
pig
group
administ
one
dose
ml
boehring
ingelheim
vetmedica
left
side
neck
vaccin
prepar
follow
mycoflex
serial
circoflex
serial
mix
togeth
mixtur
use
rehydr
ingelvac
prr
mlv
serial
done
place
ingelvac
prr
mlv
accompani
vaccin
diluent
manufactur
mix
direct
pig
vacmhpchmhp
vacprrschprrsv
group
administ
one
dose
mycoflex
ml
circoflex
ml
ingelvac
prr
mlv
ml
respect
left
side
neck
pig
unvacchmhp
unvacchprrsv
unvacunch
group
administ
one
dose
ml
phosphat
buffer
salin
pb
ph
control
dpc
day
old
pig
group
challeng
two
pathogen
prrsv
hyopneumonia
three
millilit
prrsv
inocul
contain
tissu
cultur
infect
dose
tcid
ml
intranas
administ
ml
per
nostril
five
hour
later
pig
anesthet
mixtur
mg
kg
xylazin
hydrochlorid
rompun
bayer
korea
seoul
korea
mgkg
tiletamin
hydrochlorid
mgkg
zolazepam
hydrochlorid
zoletil
virbac
korea
seoul
korea
intramuscular
inject
prepar
hyopneumonia
portion
challeng
pig
inocul
intratrach
ml
ml
per
nostril
hyopneumonia
cultur
medium
contain
color
chang
unit
ccu
ml
previous
describ
separ
challeng
done
avoid
mix
two
pathogen
could
potenti
affect
infect
pig
vacprrschprrsv
unvac
chprrsv
group
inocul
lot
prrsv
way
describ
pig
vacmhpchmhp
unvacchmhp
group
inocul
hyopneumonia
lot
manner
describ
dpc
day
old
pig
group
intranas
administ
ml
inoculum
contain
tcid
ml
nasal
swab
blood
sampl
collect
dpc
piglet
dpc
day
old
piglet
intraven
sedat
kg
dose
sodium
pentobarbit
euthan
electrocut
use
current
v
minimum
frequenc
hz
minimum
euthan
piglet
necropsi
tissu
collect
fix
h
neutral
buffer
formalin
embed
paraffin
pig
monitor
weekli
postchalleng
blind
personnel
chang
physic
condit
clinic
respiratori
diseas
symptom
respiratori
diseas
sever
score
scale
rang
normal
sever
dyspnea
abdomin
breath
previous
describ
pig
measur
live
weight
dpc
day
old
dpc
day
old
dpc
day
old
averag
daili
weight
gain
adwg
gramspigday
analyz
two
time
period
ii
adwg
calcul
differ
start
final
weight
divid
durat
stage
data
dead
remov
pig
also
includ
calcul
rna
extract
serum
sampl
assess
prrsv
viremia
previous
describ
prrsv
genom
cdna
copi
quantifi
realtim
pcr
challeng
vaccin
prrsv
strain
quantif
hyopneumonia
dna
nasal
swab
hyopneumoniae
genom
dna
copi
quantifi
realtim
pcr
dna
extract
nasal
swab
use
commerci
kit
qiaamp
dna
mini
kit
qiagen
valencia
california
usa
quantif
dna
blood
dna
extract
use
commerci
kit
qiaamp
dna
mini
kit
qiagen
perform
follow
realtim
pcr
quantifi
genom
dna
copi
number
serum
sampl
number
prrsv
hyopneumoniaespecif
secret
cell
quantifi
peripher
blood
mononuclear
cell
pbmc
describ
use
prrsv
hyopneumonia
challeng
strain
respect
morphometr
analysi
macroscop
pulmonari
lesion
previous
describ
lung
score
total
scale
point
follow
point
right
cranial
lobe
right
middl
lobe
left
cranial
lobe
left
middl
lobe
point
right
caudal
lobe
left
caudal
lobe
point
accessori
lobe
microscop
pulmonari
lesion
score
interstiti
pneumonia
rang
normal
sever
diffus
mycoplasm
pneumonia
lesion
score
base
sever
peribronchiolar
perivascular
lymphoid
tissu
hyperplasia
lung
section
score
perform
blind
defin
sourc
section
pathologist
experiment
unit
analysi
consist
data
collect
individu
piglet
oneway
analysi
varianc
anova
kruskalw
test
use
studi
anova
parametr
statist
test
analyz
differ
group
mean
kruskal
walli
test
nonparametr
analogu
anova
anova
use
variabl
show
follow
normal
distribut
adwg
prrsv
rna
hyopneumonia
dna
dna
prrsv
antibodi
titer
hyopneumonia
antibodi
titer
antibodi
titer
number
kruskalw
test
perform
variabl
without
normal
distribut
clinic
sign
macroscop
lung
lesion
score
microscop
lung
lesion
score
signific
differ
exist
group
post
hoc
multipl
comparison
test
tukey
adjust
conduct
ttest
anova
manwhitney
test
krustalw
analysi
determin
signific
differ
pairwis
group
valu
p
consid
signific
